Corient Private Wealth LLC Grows Stock Holdings in Cencora, Inc. $COR

Corient Private Wealth LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 6.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 45,818 shares of the company’s stock after buying an additional 2,598 shares during the quarter. Corient Private Wealth LLC’s holdings in Cencora were worth $15,481,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in COR. Kemnay Advisory Services Inc. bought a new stake in Cencora in the fourth quarter valued at about $25,000. Oakworth Capital Inc. bought a new position in Cencora in the 4th quarter worth about $26,000. Elyxium Wealth LLC acquired a new stake in Cencora in the 4th quarter valued at approximately $27,000. Archer Investment Corp raised its stake in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC acquired a new stake in shares of Cencora in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $281.10 on Wednesday. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a market cap of $54.69 billion, a PE ratio of 21.56, a price-to-earnings-growth ratio of 1.46 and a beta of 0.59. The firm has a fifty day moving average price of $282.77 and a two-hundred day moving average price of $323.17. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s revenue was up 3.9% on a year-over-year basis. During the same period last year, the company earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is presently 18.40%.

Cencora announced that its Board of Directors has authorized a stock buyback program on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on COR shares. Wells Fargo & Company cut their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Morgan Stanley set a $342.00 price objective on Cencora in a research note on Friday, May 8th. Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. William Blair started coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Robert W. Baird lowered their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.